Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.
Nimesulide (NIM) is a sulfonanilide nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of various inflammatory diseases and chemically unrelated to other acidic NSAIDs, such as acetylsalicylic acid (ASA) and indomethacin (INDO). We investigated the effects of NIM and of its in vivo metabolite, 4-hydroxy-NIM (OH-NIM), on the release of performed (histamine) and de novo synthesized mediators (sulfidopeptide leukotriene C4 [LTC4] and prostaglandin D2 [PGD2]) from human basophils and mast cells isolated from lung parenchyma (HLMC) and skin (HSMC). Histamine release from basophils challenged with rabbit anti-human IgE antibody (anti-IgE) was enhanced by preincubation with ASA or INDO (92.2 +/- 7.1% at 10(-3) M and 61.1 +/- 6.7% at 3 x 10(-6) M, respectively; P < .001). In contrast, NIM and its metabolite, OH-NIM (10(-6) to 10(-3) M), caused concentration-dependent inhibition (2.9 to approximately 60% and 3.7 to approximately 90%, respectively) of IgE-mediated histamine release from basophils. NIM and OH-NIM also inhibited histamine release from basophils induced by the Ca++ ionophore A23187 and different protein kinase C activators, such as 12-O-tetradecanoyl-phorbol-13-acetate, bryostatin 1 and bryostatin 5. NIM and OH-NIM also inhibited the IgE-mediated histamine release from HLMC (52.3 +/- 9.6% and 66.1 +/- 12.1% at 10(-3) M, respectively; P < .0001) and HSMC (67.3 +/- 3.7% and 77.7 +/- 12.0% at 10(-3) M, respectively; P < .0001) but had little or no effect on HLMC and HSMC activated by A23187. NIM (10(-6) to 10(-3) M) markedly inhibited the de novo synthesis of LTC4 from basophils, LTC4 and PGD2 from HLMC and PGD2 from HSMC. NIM and OH-NIM potentiated, whereas ASA and INDO reversed, the inhibitory effect of adenylate cyclase agonists, such as prostaglandin E1 and forskolin. In addition, NIM and OH-NIM reversed the enhancing effects of ASA and INDO on IgE-mediated histamine release from basophils.
Casolaro
V
V
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Italy.
Meliota
S
S
Marino
O
O
Patella
V
V
de Paulis
A
A
Guidi
G
G
Marone
G
G
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000494:pharmacology; D000595:Amino Acid Sequence; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001491:Basophils / Q000187:drug effects* / Q000378:metabolism*; D054713:Bryostatins; D000001:Calcimycin / Q000494:pharmacology; D005576:Colforsin / Q000494:pharmacology; D015936:Complement C5a / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D007073:Immunoglobulin E / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D017997:Leukotriene C4 / Q000378:metabolism; D008168:Lung / Q000166:cytology; D018942:Macrolides; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism*; D008875:Middle Aged; D008969:Molecular Sequence Data; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000378:metabolism; D012867:Skin / Q000166:cytology; D013449:Sulfonamides / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; D013449:Sulfonamides; C055891:4-nitro-2-(4'-hydroxyphenoxy)methanesulfonanilide; D005576:Colforsin; D017997:Leukotriene C4; D007073:Immunoglobulin E; D000001:Calcimycin; C046785:bryostatin 1; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a; C078062:bryostatin 5; D000527:Alprostadil; D013755:Tetradecanoylphorbol Acetate; D001241:Aspirin; D015230:Prostaglandin D2; C012655:nimesulide; D007213:Indomethacin